Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2016 | 2017 | |
|---|---|---|
| Revenue | $1.5M | $3.3M |
| Cost of revenue | $676.0K | $3.6M |
| Gross profit | $818.8K | −$316.7K |
| Gross margin | 54.8% | -9.6% |
| R&D | $759.5K | $2.9M |
| Operating income | −$634.3K | −$6.3M |
| EBITDA | −$151.8K | −$766.0K |
| Net income | −$802.5K | −$2.2M |
| Net margin | -53.7% | -65.9% |
| EPS (diluted) | -0.59 | -1.23 |
Annual figures · source: Financial Modeling Prep
No one on the platform currently holds NXNN.
No tracked institution reports a position in NXNN as of their last filing.
| Execution date | Ratio |
|---|---|
| 2018-06-28 | 1-for-14reverse |
No one on the platform has traded NXNN yet.
| $51950 |
| — |
| HCLCHealth-Chem Corporation | $0.00 | +0.00% | $73985 | — |
| NVTAQInvitae Corporation | $0.00 | -25.00% | $85948 | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.